A.O. Ospedale S.Martino
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sobrero, Alberto
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
VIVA, NCT05382741: Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): Trial

Recruiting
2
182
Europe
Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Imfinzi, Regorafenib 30 mg capsules, Stivarga
Ospedale Policlinico San Martino, Associazione Italiana per la Ricerca sul Cancro, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, Bayer
Colorectal Cancer Stage IV, No Evidence of Disease State
03/24
03/24
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed
1/2
29
Europe, US
MEN1611, Cetuximab
Menarini Group, Menarini Ricerche S.p.A.
Metastatic Colorectal Cancer
01/24
02/24

Download Options